Last reviewed · How we verify
ZL-82
At a glance
| Generic name | ZL-82 |
|---|---|
| Also known as | 600mg ZL-82, 50mg ZL-82, 100mg ZL-82, 200mg ZL-82, 600mg ZL-82 placebo |
| Sponsor | Chengdu Zenitar Biomedical Technology Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis (PHASE2)
- ZL-82 Double-blind Clinical Trial (PHASE1)
- Phase I Clinical Study of ZL-82 Tablets (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZL-82 CI brief — competitive landscape report
- ZL-82 updates RSS · CI watch RSS
- Chengdu Zenitar Biomedical Technology Co., Ltd portfolio CI